Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: Therapeutic response to meglumine antimoniate

American Journal of Tropical Medicine and Hygiene

Volumn 65, Issue 5, 2001, Pages 456-465

  Romero, G A S ^a   De Farias Guerra, M V ^a   Paes, M G ^a   De Oliveira Macedo V ^a  

^a UNIVERSITY OF BRASILIA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

MEGLUMINE ANTIMONATE;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAZIL; COMPARATIVE STUDY; FEMALE; HUMAN; LEISHMANIA; LEISHMANIA BRAZILIENSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTCOMES RESEARCH; RISK FACTOR; SCHOOL CHILD; SKIN LEISHMANIASIS; STATISTICAL MODEL; STRAIN DIFFERENCE; TREATMENT FAILURE;

EID: 0035213993     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2001.65.456     Document Type: Article

References (48)

1. Pentavalent antimonials: Old drugs for new diseases
2. Chemotherapy for leishmaniasis: Biochemical mechanisms, clinical efficacy and future strategies
3. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies
4. Practical progress and new drugs for changing patterns of leishmaniasis
5. Human leishmaniasis: Clinical. Diagnostic and chemotherapeutic developments in the last 10 years
6. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis
7. Phase 2-efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis
8. Human mucocutaneous leishmaniasis in Três Braços, Bahia-Brazil. An area of Leishmania braziliensis braziliensis transmission. II Cutaneous disease. Presentation and evolution
9. Leishmaniose no estado do amazonas. Aspectos epidemiológicos, clínicos e terapêuticos
10. A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: Extensive follow-up studies (up to 10 years)
11. V) in American cutaneous leishmaniasis. A five years follow-up study of 15 patients
12. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala
13. Efficacy of a short course (10 days) of high-dose meglumine antimoniate with or without interferon-γ in treating cutaneous leishmaniasis in Guatemala
14. Safety and efficacy of highdose sodium stibogluconate therapy of American cutaneous leishmaniasis
15. Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine
16. Topical paromomycin methylbenzetonium chloride plus parenteral meglumine antimoniate as treatment of American cutaneous leishmaniasis: Controlled study
17. Treatment of American cutaneous leishmaniasis: A comparison between low dosage (5 mg/kg/day) and high dosage (20 mg/kg/day) antimony regimens
18. R e antimoniato de meglumina no tratamento da leishmaniose cutânea: I. Eficácia e segurança
19. Report of WHO Expert Committee
20. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients
21. A pentamidina - Excelente terapêutica da leishmaniose cutânea. Esquema de tratamento idealizado na guiana francesa em dose única
22. Predominance of Leishmania braziliensis in the regions of Três Braços and Corte de Pedra, Bahia, Brazil
23. The size of a clinical trial
24. Sensitivity of a vacuum aspiratory culture technique for diagnosis of localized cutaneous leishmaniasis in an endemic area of Leishmania (Viannia) braziliensis transmission
25. Sensitivity of lymph node aspiration in localized cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis
26. A rapid and sensitive method for the identification of Leishmania with monoclonal antibodies using fluorescein-labeled avidin
27. A general classification of New World Leishmania using numerical zymotaxonomy
28. Selection of a specific skin test antigen for American visceral leishmaniasis
29. Measurement of delayed skin-test responses
30. Características físico-químicas do antimoniato de meglumina em diferentes condições de armazenamento
31. Differential determination of antimony (III) and antimony (V) by indirect spectrophotometry with chromium (VI) and diphenylcarbazide, after reduction of antimony (V)
32. Calculating confidence intervals for proportions and their differences
33. Clinical and immunopathological aspects of disseminated cutaneous leishmaniasis
34. Evolution classification and geographical distribution of Leishmania
35. Cura espontânea da leishmaniose causada por Leishmania (Viannia) braziliensis em lesões cutâneas
36. Epidemiological aspects of human cutaneous leishmaniasis in French Guiana
37. A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate
38. Drug resistance in leishmaniasis: Its implication in systemic chemotherapy of cutaneous and mucocutaneous disease
39. Cell mediated immunity in American cutaneous and mucosal leishmaniasis
40. Leishmania-reactive CD4+ and CD8+ T cells associated with cure of human cutaneous leishmaniasis
41. Characterization of the immune response in subjects with self-healing cutaneous leishmaniasis
42. Long-term follow-up of patients with Leishmania (Viannia) braziliensis infection and treated with Glucantime
43. Down-regulation of Th1 type of response in early human American cutaneous leishmaniasis
44. Efficacy of 28-day and 40-day regimens of sodium stibogluconate (Pentostam) in the treatment of mucosal leishmaniasis
45. Randomized, double-blind study of stibogluconate plus human granulocyte macrophage colony-stimulating factor versus stibogluconate alone in the treatment of cutaneous leishmaniasis